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Background/Aims: Recent findings suggest an involvement of insulin-like growth factor-1 (IGF-1) in the pathogenesis of many psychiatric disorders; however, there is lack of data regarding IGF-1 in patients with obsessive–compulsive disorder (OCD). The aims of the present study were: 1) to analyze putative alterations of IGF-1 serum content in patients with OCD compared to patients with major depressive disorder (MDD) and healthy controls; 2) to analyze putative changes of IGF-1 levels during drug treatment in subjects with OCD compared to patients with MDD. 
Methods: We recruited 40 OCD patients, 37 MDD patients and 43 healthy controls. All participants were adults. Serum IGF-1 levels were measured by ELISA method on venous blood samples collected at baseline and after 10±1 weeks of drug treatment. 
Results: IGF-1 levels were increased in OCD patients compared to controls (149.9±60.2 ng/ml versus 121.2±51.6 ng/ml; p=0.040). No correlations were observed between baseline IGF-1 levels, clinical features and response to treatment at follow-up in OCD or MDD patients. No changes in serum IGF-1 were observed after drug treatment. 
Conclusion: Our results show for the first time that serum IGF-I levels are altered in patients with OCD. Further research on the role of IGF-1 in OCD is warranted.
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1. Introduction
Insulin-like growth factor-1 (IGF-1) is both a hormone of the somatotropic axis acting under the control of pituitary growth hormone (GH) and a local humoral factor that plays a crucial role as regulator of homeostasis in all tissues. Liver cells secrete the majority of serum IGF-1, although several tissues produce this growth factor and many types of cells express IGF-1 receptors. In the central nervous system (CNS), IGF-1 is considered a neurotrophic factor involved in neuronal growth and a modulator of brain activity with a critical role in neurogenesis and differentiation, as well as neurotransmitter synthesis and release [1-5]. Many brain areas express GH and IGF-1 receptors and IGF-1 can pass the blood-brain barrier through a transporter-mediated mechanism [6]. IGF-1 can also be produced in the brain and thus act via paracrine mechanisms [7], but the expression levels of IGF-1 in the adult brain are low, suggesting that the CNS may utilize IGF-1 from peripheral sources [2]. IGF-1 may also modulate the receptor functions of neurotransmitters such as serotonin, noradrenaline and dopamine, involved in the pathogenesis of many psychiatric disorders [8]. Many studies showed an increase of IGF-1 peripheral levels in different psychiatric diseases: major depressive disorder, bipolar disorder and schizophrenia [7,9-15]. 
With regard to the relationship between psychopharmacological treatment and IGF-1 levels, data in the literature are controversial: some studies reported that IGF-1 expression was increased by antidepressant administration in the rat brain [16-19] and in cerebrospinal fluid of depressed patients being treated with antidepressants [7], while others indicated a decrease of serum or plasma IGF-1 concentrations in depressed patients responding to treatment with various antidepressants [7,10]. Moreover, Li and colleagues, comparing a sample of patients with major depressive disorder (MDD) with healthy controls showed that the alteration in the diurnal rhythms of IGF-1 release persisted 8 weeks after antidepressant treatment [20]. Furthermore, recent findings showed that IGF-1 levels did not decrease in manic patients after 6 weeks of psychopharmacological treatment [13] nor in schizophrenic patients after 1 year of antipsychotic therapy [14].
To date data on the potential role of IGF-1 in the pathogenesis of obsessive-compulsive disorder (OCD) are scarce. A few studies investigated whether OCD was characterized by a significant pathology of the peripheral somatotropic axis [21-23]. The results showed that responses of GH (that stimulates IGF-1 hepatic production) to growth-hormone-releasing-hormone (GHRH) stimulation were blunted in OCD patients, thus suggesting impairment in the mechanisms regulating GH secretion in OCD [23]. In a subsequent study the nocturnal GH secretion in patients with OCD was found to be altered compared to controls [24]. Hence available data seem to suggest a complex dysfunction of the somatotropic axis in OCD; the etiopathogenetic significance of this alteration is still obscure.
Recently, we performed a case-control study investigating serum concentrations of the brain derived neurotrophic factor (BDNF) in drug-naïve OCD patients. The data evidenced a significant reduction of serum BDNF levels in OCD patients compared to controls: this finding corroborates the hypothesis of an alteration of neurotrophins and growth factors in the OCD pathogenesis [25]. Remarkably, previous works suggest a potential link and a cooperative effect between BDNF activity and IGF-1 [26-29]. To date, whether peripheral IGF-1 is altered in OCD patients has not yet been established. Further, there are no data regarding alterations of IGF-1 serum levels following psychopharmacological treatment in patients with OCD.
In the light of these considerations we resolved to assess IGF-1 levels in OCD patients compared to healthy subjects; in addition, since in the literature definite evidence exists on the alteration of IGF-1 levels in MDD, we examined IGF-1 serum content in MDD patients also. In particular, the aims of the present study were: 1) to assess serum content of IGF-I in drug-naïve OCD patients compared to age- and sex-matched drug-free MDD patients and healthy controls; 2) to analyze putative changes in IGF-I serum concentrations during drug treatment in OCD patients compared to subjects with MDD. 

2. Materials and Methods
2.1. Participants
For the purposes of this study we recruited 40 unrelated OCD patients at the Psychiatric Clinic of the Neuroscience Department (University of Turin – Italy). Inclusion criteria were: (a) principal diagnosis of OCD according to DSM-IV criteria; (b) minimum total score of 16 on the Yale–Brown Obsessive Compulsive Scale (Y-BOCS) [30]; (c) at least 18 years of age; (d) willingness to voluntarily participate in the study. Exclusion criteria were: (a) current or previous diagnosis of organic mental disorder, substance-related disorder, schizophrenia or other psychotic disorders, (b) current diagnosis of depressive disorder according to DSM-IV criteria; (c) uncontrolled or serious medical condition; (d) any current or past psychopharmacological treatments.
In parallel, we recruited 37 unrelated patients with MDD at IRCCS San Giovanni di Dio “Fatebenefratelli” (Brescia – Italy). Inclusion criteria were: (a) current major depressive episode according to DSM-IV criteria; (b) at least 18 years of age; (c) willingness to voluntarily participate in the study. Exclusion criteria were: (a) current or previous diagnosis of organic mental disorder, substance-related disorder, schizophrenia or other psychotic disorders, bipolar disorder according to DSM-IV criteria; (b) current or previous diagnosis of obsessive-compulsive disorder according to DSM-IV criteria; (c) uncontrolled or serious medical condition; (d) any psychopharmacological treatments in the 3 months before enrolment.
Also, we enrolled a control group of 43 unrelated volunteers matched for gender and age with the patient groups at IRCCS San Giovanni di Dio “Fatebenefratelli” (Brescia – Italy). None of the subjects had a current or past DSM-IV psychiatric diagnosis according to the clinical interview and to the Mini-International Neuropsychiatric Interview (M.I.N.I.) or suffered from any medical diseases or was in pharmacological treatment (including oral contraceptives). Also, none of the control subjects had first-degree relatives with a current or past DSM-IV psychiatric diagnosis.
After the recruitment and a blood sampling at baseline to evaluate IGF-1 serum levels, we assigned all 40 OCD and 37 MDD patients to pharmacological treatment with serotonin re-uptake inhibitors (SRIs) within one week. OCD and MDD patients were treated with one of the following SRIs: citalopram (n=9 OCD patients and n=9 MDD patients; initial dose 20 mg/d, up to a daily dose of 40 mg), fluvoxamine (n=9 OCD patients and n=9 MDD patients; initial dose 100 mg/d, up to a dose of 300 mg/d), paroxetine (n=9 OCD patients and n=9 MDD patients; initial dose 20 mg/d, up to a daily dose of 50 mg), sertraline (n=10 OCD patients and n=10 MDD patients; initial dose 50 mg/d, up to 200 mg/d). Some OCD patients were also given clomipramine (n=3; initial dose: 25 mg/d, up to 250 mg/d).
We carried out the investigation in accordance with the latest version of the Declaration of Helsinki. The local ethics committees approved the study. We obtained written informed consent from each subject after complete description of the study. 

2.2. Assessment
Socio-demographic characteristics of recruited patients, diagnostic evaluation and information about onset and course of the disease were obtained through the administration of a semi-structured interview that we developed and used in previous studies [31-33]. In particular, principal diagnosis and axis I and axis II comorbidities were recorded by means of the Structured Clinical Interview for DSM-IV Axis I and II Disorders [34-35].
In addition, we administered the following clinical rating scales at baseline (T0) and at follow-up (after 10±1 weeks of drug treatment): Y-BOCS, 17-item Hamilton Rating Scale for Depression (HAM-D) and Clinical Global Impression (CGI). In line with previous studies [36-39] we defined response to treatment at follow-up as a percentage decrease of at least 25% from baseline Y-BOCS in OCD patients and of at least 50% from baseline HAM-D in MDD patients.

2.3 Biological sampling procedure
We collected venous blood samples from all study participants at T0 (baseline), before OCD and MDD patients started drug treatments. Next, all patients began a drug treatment with SRIs within one week after blood sampling. Then, 10±1 weeks after initiation of drug treatment we again collected venous blood samples to evaluate the changes in IGF-1 serum levels during treatment (follow-up). In the Brescia site the whole sample of MDD patients underwent the follow-up blood sampling, whereas in the Turin site 18 out of the 40 OCD patients were available for the follow-up blood draw because of organizational issues. 

2.3. Serum IGF-I determination
We collected venous blood samples of patients and controls in anticoagulant-free tubes (for serum preparation) in the morning after an overnight fast (between 08:00 and 09:00 a.m.). We kept serum tubes at room temperature for 2 hours followed by 1 hour at 4 °C before serum separation by centrifugation (1,620×g for 15 min). We stored serum samples at −80 °C till the time of assay. 
IGF-1 levels were measured by an ELISA method using Human IGF-I Quantikine ELISA Kit (R&D System, MN, USA), according to the manufacturer’s instructions. We pretreated serum samples according to the kit protocol and we multiplied the concentrations obtained from the standard curve by the dilution factor, 100. We performed all IGF-1 analyses in duplicate. We ran patient and control samples together in the same plates. The intra-assay coefficient of variation was <5 %. The IGF-I content was expressed as ng of human recombinant IGF-I protein/ml of serum.

2.4. Statistical analyses
We evaluated differences among OCD and MDD patients and controls in terms of gender (by Pearson’s Chi-Square), age, body mass index (BMI) and IGF-1 serum levels (by analysis of variance – ANOVA – model with Tukey's post-hoc tests). We tested within group changes in terms of Y-BOCS and HAM-D scores using paired t-tests as well. Linear correlation between IGF-1 baseline level and clinical measures was calculated by Pearson’s correlation coefficient. 
Because of violation of Normality assumption, we adopted non-parametric Kruskal Wallis test to detect significant differences in IGF-1 levels at baseline between OCD patients, MDD patients and controls. Finally, we assessed longitudinal changes of IGF-1 levels during treatment by non-parametric Wilcoxon test. 
Statistical significance was set at p-value<0.050. Analyses were performed using IBM SPSS Statistics for Windows, Version 21.0.

3. Results
The socio-demographic and clinical features of OCD and MDD patients are presented in Table 1. There were no statistically significant differences among OCD patients, MDD patients and controls in terms of age, gender and BMI. In the OCD group, the majority of patients showed an insidious onset and a chronic course. Information about education and working status were available for OCD and MDD patients only: OCD patients had higher levels of education than MDD patients (p=0.046) while there were no statistically significant differences in the proportion of patients working for pay in the OCD vs MDD groups. There were no statistically significant differences between OCD and MDD patients in terms of CGI scores at baseline while MDD patients showed significantly higher scores at HAM-D compared to OCD patients (p<0.001).
All the recruited patients were treated with SRIs. There were no statistically significant differences in the types of medication administered to OCD and MDD patients. The symptomatology ameliorated during treatment showing a significant reduction of Y-BOCS scores in obsessive-compulsive patients (mean score at baseline=22.5, SD=4.9 vs mean score at follow-up=15.4, SD=6.1; t=11.512; p<0.001) and a significant reduction in HAM-D scores in depressed patients (mean score at baseline=19.7, SD=2.6 vs mean score at follow-up=7.2, SD=6.0; t=12.2; p<0.001). 30 MDD patients (81,1%) and 29 OCD patients (74.4%) were defined as “drug responders” at follow-up.

	OCD(N=40)	MDD(N=37)	Controls(N=43)
	N / Mean	% / S.D.	N / Mean	% / S.D.	N / Mean	% / S.D.
Age:	38.7	13.3	42.4	11.9	42.3	11.3




Age at onset, years:	19.6	5.1	40.3	11.8		
HAM-D-17:**	6.5	3.0	19.7	2.6		
CGI:	4.1	0.6	4.2	0.8		
Y-BOCS:Total scoreObsession subscoreCompulsion subscore	22.511.711.2	4.92.63.0				

Table 1. Socio-demographic and clinical characteristics of OCD and MDD patients and controls: we described relevant features of the OCD and MDD patient samples and of the control group in terms of mean and standard deviation (SD), if quantitative, and in terms of frequencies and proportions otherwise. *p<0.05 **p<0.001

Serum IGF-I levels measured at T0 (baseline) were increased in drug-naïve OCD patients (mean 149.9, SD=60.2 ng/ml) versus controls (mean 121.2, SD=51.6 ng/ml) (p=0.040) (Fig. 1). We observed no significant differences at T0 between OCD and MDD patients and between MDD patients and controls. We evidenced no correlations between IGF-1 baseline levels and symptomatology measured by Y-BOCS and CGI in OCD patients and by HAM-D and CGI in MDD patients. In addition, no correlation or association (for categorical variables) emerged between baseline IGF-1 and clinical characteristics as age at onset, type of onset, type of course or clinical response at follow-up in the OCD sample nor between baseline IGF-1 levels and clinical response at follow-up in the MDD sample. IGF-1 baseline levels were only inversely correlated to age at onset in MDD patients (r=-0.40, p=0.014). 
As mentioned before, for the analysis of longitudinal changes in IGF-1 levels during treatment it was possible to carry out a follow-up blood sampling in the whole MDD sample (n=37) and in a sub-set of 18 out of 40 OCD patients. There were no significant differences in the socio-demographic and clinical characteristics of the sub-set who underwent the follow-up blood draw compared to the rest of the OCD patients and with the whole OCD sample. Also, the clinical response rates of the OCD patients with the follow-up blood draw compared to those without (77.8% vs 66.7%; p=0.342) and with the whole OCD sample (77.8% vs 74.4%; p=0.447) showed no significant differences.

Figure 1. Mean IGF-1 serum levels at baseline (ng/ml).

Paired sample t-tests did not show any difference between IGF-1 baseline and follow-up levels (for the OCD subgroup baseline IGF-1 mean level 131.4, SD=50.3 ng/ml vs follow-up mean level 126.6, SD=50.0 ng/ml; p=0.215; for subjects with MDD baseline IGF-1 mean level 128.1, SD=48.3 ng/ml vs follow-up mean level 122.8, SD=46.8; p=0.420). We found no correlations between baseline-to-follow-up IGF-1 variation and response to treatment in any of the samples.

4. Discussion 
The present study is a part of a multicenter research protocol aimed to investigate the role of neurotrophic factors in the pathogenesis of psychiatric disorders. To our knowledge, this is the first study focused on the relationship among IGF-1, OCD and response to SRI drug treatment. Also it is the first study comparing IGF-1 levels in OCD and MDD patients.
The characteristics of the two clinical samples reflect those of the populations suffering respectively from OCD and MDD. In the OCD sample the female/male ratio was 1,2:1, the mean age at onset of the disorder was younger, and the course was mostly chronic. In the MDD sample the female/male ratio was 3,6:1 and the mean age at onset of the disorder was older. None of the recruited patients was on medication at the time of the first assessment point. 
The main result of the study showed a statistically significant increase of the IGF-1 serum content in OCD patients versus controls at baseline. We observed no significant differences in baseline IGF-1 levels between OCD and MDD patients or between MDD patients and controls. An inverse correlation between baseline IGF-1 levels and age at onset emerged in MDD patients. 
Consistent evidence supports a positive effect of IGF-1 in the brain: a trophic action might be exerted by circulating IGF-1 on glutamatergic synapses modulating synaptic LTP and hippocampal cognitive functions [40]; in mice both central and peripheral administration of IGF-1 may induce antidepressant- and anxyolitic-like actions that are similar to those of chronic antidepressant drug treatment [41-43]. Based on such preclinical evidence, we would expect low IGF-1 levels in mental illness. On the contrary, IGF-1 serum levels show an increase in many different psychiatric diseases (MDD, bipolar disorder, first-episode schizophrenia, autism spectrum disorders) and recent papers also prove that IGF-1 levels are raised in neurologic disorders such as Parkinson’s disease, multiple system atrophy, etc [9-14; 44-45]. These findings suggest that IGF-1 elevation in mental disorders could exert counter-regulatory neuroprotective effects. In fact in these pathologies such an increase in the periphery might be a response to IGF-1 low bioavailability in the CNS [11,14]. IGF-1 serum content derived by the liver synthesis might participate to a more complex mechanism – involving several key neurotrophic factors, such as BDNF - aimed at stimulating neural systems required for the reversal of damages induced by stress in general and by psychiatric disease in particular [25,46]. 
Moreover the augmentation in serum might be part of a compensative mechanism caused by alterations in other proteins regulating the IGF system such as those observed in the high-affinity binding protein (IGFBP) that bind the IGFs and transport the growth factors to their site of action or sequester them within tissues regulating the bioavailability [47]. At this regard increased IGF-1 serum levels were observed in BD patients [48,49] and, in parallel, post-mortem studies indicated a reduction of IGFBP2 in patients’ brains [50]. 
Our findings reported for the first time an increase of IGF-1 in drug-naïve OCD patients, further supporting the hypothesis that a peripheral increase of IGF-1 might be an alteration shared by several mental illnesses [51]. Such evidence in OCD is also sustained by our previous report of an alteration of peripheral BDNF – a neurotrophic factor working in close cooperation with IGF-1 [25].  
On the other hand, we could not show alterations in IGF-1 serum levels in MDD patients, in contrast with other findings reporting an increase in the growth factor concentration [7,52]. These differences might be due to patients’ clinical characteristics such as age at onset, since we found an inverse correlation of IGF-1 with this parameter, or illness severity: in this regard, the depressive symptomatology in our sample (mean baseline HAM-D score: 19.7 ± 2.6) is milder that that of other studies [7,52], due to the recruitment of drug-free patients, a choice that excluded subjects with a more severe disorder. However, other studies [53-55] reported contrasting results and often observed a gender effect in the correlation between IGF-1 levels and depression incidence. Another possible reason explaining the difference in our results compared to other studies and the discrepancy between our findings in OCD and MDD patients might be previous drug exposure: MDD patients in our sample had stopped all medications at least three months before enrolment, while OCD patients were drug-naïve. However, there is no evidence that antidepressants effects on IGF-1 levels may persist after treatment interruption. In any case, in our study we chose a prolonged medication-free period (3 months) to allow complete washout of any treatment MDD patients were taking and therefore minimize any possible interference with IGF-1 levels measurements. Also, it must be mentioned that participants to previous studies showing an elevation in IGF-1 levels in subjects with MDD either stopped their medication just a few days before baseline blood sampling [7] or were on medication at the time of the blood collection [52]. Therefore it is unlikely that any medications our patients were taking three months before enrollment hampered the relevance of our findings.
The second main finding in our study is that we detected no differences in IGF-1 serum levels before and after drug treatment with SRIs, although the majority of OCD and MDD patients with a IGF-1 follow-up evaluation showed a clinical response (respectively 77.8% and 81.1%). 
These results are in contrast with studies showing a reduction of IGF-1 peripheral levels in depressed patients during pharmacotherapy [7-10]. However, as mentioned before, more recent works have found that in MDD patients antidepressant treatment does not normalize disruptions in the diurnal rhythm of IGF-1 release, suggesting that these long-term neurobiological changes may play a role in vulnerability to recurrence [20]. Also, bipolar patients during manic episodes and subjects with schizophrenia do not show a decrease in IGF-1 levels after respectively 6 weeks or 1 year of drug treatment [13-14]. On the other hand, in our study the absence of significant changes in IGF-1 levels after treatment in OCD patients could be related to the IGF-1 slightly lower levels at baseline compared to the whole OCD sample.
In conclusion, our results reveal for the first time that serum IGF-I levels are increased in drug-naïve patients with OCD. Since such evidence is a common finding in many psychiatric disorders, our data support the hypothesis that IGF-1 might be an aspecific marker of CNS distress. We also showed that IGF-1 levels are not modulated by SRIs drug treatment. However, this finding should be considered in the light of some limitations of the study: the small size of the OCD subgroup who underwent the blood draw at follow-up, the mild depressive symptomatology in the MDD group at baseline and the absence of a control group in the treatment effect analysis. Another possible limitation is the comparison of IGF-1 levels between a group of drug-naïve patients (OCD subjects) and a group of drug-free patients (MDD subjects), although MDD patients had not taken any psychopharmacological treatment for at least three months before recruitment.
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